日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

CD40激动剂mitazalimab联合mFOLFIRINOX方案治疗未经治疗的转移性胰腺癌:OPTIMIZE-1研究中与疗效相关的生物标志物

Jean-Luc Van Laethem ,Karen Geboes ,Ivan Borbath ,Teresa Macarulla Mercade ,Aurélien Lambert ,Philippe Cassier ,Hans Prenen ,Emmanuel Mitry ,Jean-Frédéric Blanc ,Lorenzo Pilla ,Jaime Feliu ,Mercedes Rodriguez Garrote ,Roberto Antonio Pazo-Cid ,Inmaculada Gallego ,Karin Enell Smith ,Karin Nordbladh ,David Gomez Jimenez ,Peter Ellmark ,Yago Pico de Coaña ,Sumeet Vijay Ambarkhane ,Gregory L Beatty ,Eileen M O'Reilly

Maintenance chemotherapy in biliary tract tumours in the era of immuno-chemotherapy

免疫化疗时代胆道肿瘤的维持化疗

Lamarca, A; Adeva, J; Ales Díaz, I; Alvarez Gallego, R; Muñoz Martín, A J; Macarulla Mercade, T

Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study

晚期肝细胞癌患者接受肿瘤电场联合索拉非尼治疗:HEPANOVA II期研究结果

Gkika, Eleni; Grosu, Anca-Ligia; Macarulla Mercade, Teresa; Cubillo Gracián, Antonio; Brunner, Thomas B; Schultheiß, Michael; Pazgan-Simon, Monika; Seufferlein, Thomas; Touchefeu, Yann